Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):

	Year ended December 31,
	2024		2023
Collaborative arrangement revenue	$	4,055	$	6,036
Less:
OCU400	6,846		7,318
OCU410 and OCU410ST	3,653		4,029
NeoCart	489		1,336
COVAXIN	25		8,824
Inhaled mucosal vaccine platform	2,464		629
OCU200	379		713
Unallocated costs:
Research and development personnel costs	12,992		13,868
Facilities and other support costs	2,984		1,507
Other (a)	2,294		1,349
Total research and development	32,126		39,573
General and administrative	26,686		31,994
Total operating expenses	58,812		71,567
Loss from operations	(54,757)		(65,531)
Other income (expense), net	703		2,453
Segment and consolidated net loss	$	(54,054)	$	(63,078)

(a) Other expenses include travel for research and development and a clinical and regulatory data repository system for each program.